Milestone Pharmaceuticals
OverviewSuggest Edit
Milestone Pharmaceuticals is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of paroxysmal supraventricular tachycardia (PSVT).
The Company employs a lean and cost efficient model which has the effect of minimizing overhead and focusing spending on the programs. It has assembled a core seasoned management team with expertise in cardiovascular clinical drug development, regulatory affairs, chemistry and manufacturing, and commercial preparedness which is guided by world-class key opinion leaders (KOLs) and advisors.
| Type | Public | |
| Founded | 2005 | |
| HQ | Montréal, CA | Map |
| Website | milestonepharma.com |
Recent NewsAll News
- Milestone Pharmaceuticals Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT
- Milestone Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Corporate Update
- Thinking about buying stock in Milestone Pharmaceuticals, Advanced Micro Devices, CymaBay Therapeutics, Pfizer Inc, or AT&T?
- Milestone (MIST) Alert: Johnson Fistel Launches Investigation into Milestone Pharmaceuticals Inc.; Investors Suffering Losses Encouraged to Contact Firm
Key People/Management at Milestone Pharmaceuticals
Joseph Oliveto
President & CEO
Philippe Douville
Founder and Strategic Advisor
Robert J. Wills
Chairman of the Board
Francis Plat
Chief Medical Officer
Lisa M. Giles
Independent Non-Executive Director
Lorenz Muller
Chief Commercial Officer
Milestone Pharmaceuticals Office Locations
Milestone Pharmaceuticals has offices in Montréal and Charlotte
Montréal, CA (HQ)
420 1111 Boulevard Dr.-Frederik-Philips
Charlotte, NC, US
7422 Carmel Executive Park Dr #300
Milestone Pharmaceuticals Financials and Metrics
Milestone Pharmaceuticals Revenue
| USD | |
|---|---|
Net income (Q2, 2020) | (13.0m) |
EBIT (Q2, 2020) | (13.1m) |
Market capitalization (26-Feb-2021) | 209.2m |
Closing stock price (26-Feb-2021) | 7.2 |
Cash (30-Jun-2020) | 53.4m |
EV | 156.0m |
Milestone Pharmaceuticals's current market capitalization is $209.2 m.
Annual
Annual
Annual
| USD | FY, 2017 |
|---|---|
Financial Leverage | 1.1 x |
Milestone Pharmaceuticals Cybersecurity Score
Milestone Pharmaceuticals Online and Social Media Presence
Milestone Pharmaceuticals's Trends
Milestone Pharmaceuticals News and Updates
November 18, 2020
Milestone Pharmaceuticals Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT
– RAPID and completed NODE-301 studies could potentially fulfill efficacy requirement for future NDA for etripamil in patients with PSVT – – RAPID investigates efficacy of second dose of etripamil for patients with persistent PSVT – – RAPID results expected late 2021/early 2022 – MONTREAL...
November 13, 2020
Milestone Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., Nov. 13, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended...
July 23, 2020
Thinking about buying stock in Milestone Pharmaceuticals, Advanced Micro Devices, CymaBay Therapeutics, Pfizer Inc, or AT&T?
NEW YORK, July 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MIST, AMD, CBAY, PFE, and T. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
March 24, 2020
Milestone (MIST) Alert: Johnson Fistel Launches Investigation into Milestone Pharmaceuticals Inc.; Investors Suffering Losses Encouraged to Contact Firm
SAN DIEGO, March 23, 2020 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Milestone Pharmaceuticals Inc. (NASDAQ: MIST) ("Milestone or the "Company") for violations of federal securities laws. On or about May 9, 2019, Milestone...
August 29, 2019
Milestone Pharmaceuticals to Participate in Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., Aug. 29, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. today announced that members of the Milestone management team will participate in the following September investor conferences: Citi's 14th Annual Biotech Conference on Thursday, September 5, 2019...
May 21, 2019
Milestone Pharmaceuticals Presents Studies on the Economic Impacts of PSVT at the ISPOR 2019 Annual Meeting
MONTREAL and CHARLOTTE, N.C., May 21, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the...
Milestone Pharmaceuticals Blogs
November 11, 2020
Milestone Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Milestone Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Content Import
Wed, 11/11/2020 - 07:01
Milestone Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
November 11, 2020
This release is a ba…
October 22, 2020
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
Content Import
Thu, 10/22/2020 - 16:02
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
October 22, 2020
…
September 22, 2020
Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments
MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Lisa Giles and Robert Wills to its
August 12, 2020
Milestone Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Corporate Update
Milestone Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Corporate Update
Content Import
Wed, 08/12/2020 - 07:01
Milestone Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Corporate Update
August…
August 06, 2020
Milestone Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference
Milestone Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference
Content Import
Thu, 08/06/2020 - 07:02
Milestone Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference
August 06, 2020
This release is a ba…
May 27, 2020
Milestone Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference
MONTREAL and CHARLOTTE, N.C. , May 27, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto , President and Chief Executive
Milestone Pharmaceuticals Frequently Asked Questions
When was Milestone Pharmaceuticals founded?
Milestone Pharmaceuticals was founded in 2005.
Who are Milestone Pharmaceuticals key executives?
Milestone Pharmaceuticals's key executives are Joseph Oliveto, Philippe Douville and Robert J. Wills.
How many employees does Milestone Pharmaceuticals have?
Milestone Pharmaceuticals has 30 employees.
Who are Milestone Pharmaceuticals competitors?
Competitors of Milestone Pharmaceuticals include Biogen, Inovio Pharmaceuticals and MyoKardia.
Where is Milestone Pharmaceuticals headquarters?
Milestone Pharmaceuticals headquarters is located at 420 1111 Boulevard Dr.-Frederik-Philips, Montréal.
Where are Milestone Pharmaceuticals offices?
Milestone Pharmaceuticals has offices in Montréal and Charlotte.
How many offices does Milestone Pharmaceuticals have?
Milestone Pharmaceuticals has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies